Ozempic Uses: FDA Uses, How It Works, and Side Effects

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article belongs to the PlexusDx Education Hub, covering GLP-1 therapies and the genetics behind metabolic decisions. Browse all Peptides & GLP-1 education.

Ozempic is among the most-searched names in the GLP-1 receptor agonist landscape as of April 2026. This reference pairs the approved uses with the mechanism that produces them and the safety profile that bounds them — a compact way to see how the molecule's job, its biology, and its risks fit together, before turning to the genetics that sit underneath. Read together, those threads explain not just what the drug does but why it does it and where its limits lie.

The FDA-approved uses at a glance

Ozempic is Novo Nordisk's brand of semaglutide, a GLP-1 receptor agonist. Ozempic is FDA-approved for type 2 diabetes (2017), Wegovy for chronic weight management (2021), and Rybelsus for type 2 diabetes (2019) as the oral form. All three share the same active ingredient but carry separate FDA labels and separate insurance-coverage logic, which is why the specific product matters as much as the molecule.

How the mechanism creates those uses

GLP-1 receptor agonists and GIP/GLP-1 dual agonists act on appetite regulation, satiety signaling, and gastric emptying, reducing caloric intake through mechanism-mediated changes rather than simple willpower. Body-weight reduction depends on the specific compound, the dose, adherence, and individual factors. FDA-approved weight-management dosing is titrated upward from a starting dose over several weeks per each product's label. In other words, the approved uses are downstream of one shared biological action.

Evidence behind the uses

The claims attached to these uses come from a substantial trial base: SURMOUNT and SURPASS for tirzepatide, STEP and SUSTAIN for semaglutide, AWARD for dulaglutide, and LEAD and LEADER for liraglutide. Effect sizes on body weight, A1C, and cardiovascular endpoints vary by population, dose, and primary endpoint, and the work appears in The New England Journal of Medicine, The Lancet, and The Lancet Diabetes & Endocrinology. Bring the outcomes relevant to your situation to a provider.

Side effects and contraindications

GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — and are typically most pronounced during dose escalation. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration.

Why identical uses produce different results

The approved use is the same for two people, yet outcomes diverge. Part of that variation traces to differences in metabolic biology that predate any prescription, which is where the upstream genetic picture becomes relevant to how the same use plays out.

The genetics underneath the uses

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1 signaling, appetite, and energy balance. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights. It never predicts response to any one compound, but it maps the terrain the approved uses act within. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

How mechanism, use, and risk fit together

The cleanest way to hold all of this in mind is to see the three pieces as one chain. A shared mechanism acting on appetite, satiety, and gastric emptying produces the approved uses, and that same biological reach is why the side-effect profile centers so heavily on the gut. The benefits and the common complaints trace back to the same actions rather than to unrelated quirks of the drug.

Seen this way, the side effects stop looking arbitrary and start looking like the predictable shadow of the mechanism. That framing does not make them trivial, but it does make them easier to anticipate and discuss. A provider weighing a use against a person's history is really weighing how that individual is likely to experience the mechanism, which is where the upstream biology becomes worth understanding. That single-chain view, from mechanism to approved use to expected side effects, is the most durable way to keep the whole picture straight.

Frequently Asked Questions

What are the main FDA-approved uses?

Across the semaglutide family, Ozempic is approved for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus for type 2 diabetes as the oral form. Other class products add cardiovascular risk reduction and, for Zepbound, obstructive sleep apnea. Each product carries its own label and coverage logic.

How does one mechanism produce several uses?

The class acts on appetite regulation, satiety signaling, and gastric emptying, reducing caloric intake through mechanism-mediated change. Those same actions support glycemic control and weight reduction, so a single biological mechanism underlies multiple approved uses, with results depending on compound, dose, adherence, and individual factors.

Does a genetic test change which uses apply to me?

No. The Precision Peptide Genetic Test does not predict response or assign an indication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, offering upstream context that applies across every approved use in the class.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.